TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25734159

Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (3.75 µg HA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine without AS03 adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (7.5 µg HA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inactivated influenza A/Indonesia/05/2005 (H5N1) virus vaccine with AS03 adjuvant (15 µg HA)
Number of subjects: 0
Study: 25734163

Group type: EXPERIMENTAL
Intervention: WHO-TB screening followed by clinical scoring
Number of subjects: 812

Group type: COMPARATOR
Intervention: WHO-TB screening alone
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Clinical scoring algorithm (0-1 points)
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Clinical scoring algorithm (≥4 points)
Number of subjects: 812

Group type: COMPARATOR
Intervention: WHO-TB screening
Number of subjects: 812
Study: 25734253

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 27
Study: 25734254

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.06-0.24 mg/kg · d)
Number of subjects: 86
Study: 25734940

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 27
Study: 25735260

Group type: EXPERIMENTAL
Intervention: Endovascular aortic aneurysm repair (EVAR) with Heli-FX Aortic Securement System
Number of subjects: 221
Study: 25735651

Group type: EXPERIMENTAL
Intervention: Olaparib maintenance therapy
Number of subjects: 0
Study: 25735902

Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tube (cETT) with air leak technique and continuous positive airway pressure of 20 cmH2O
Number of subjects: 27
Study: 25736422

Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cultural views and concerns addressed by clinicians
Number of subjects: 30
Study: 25736912

Group type: EXPERIMENTAL
Intervention: Rituximab monotherapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: CHOP-based chemotherapy
Number of subjects: 70
Study: 25738854

Group type: EXPERIMENTAL
Intervention: Deceleration capacity of heart rate
Number of subjects: 5730

Group type: COMPARATOR
Intervention: Modified early warning score
Number of subjects: 5730

Group type: EXPERIMENTAL
Intervention: Deceleration capacity implemented into the modified early warning score model
Number of subjects: 5730

Group type: EXPERIMENTAL
Intervention: Deceleration capacity
Number of subjects: 5730
Study: 25738921

Group type: EXPERIMENTAL
Intervention: Indigo Naturalis (Lindioil) applied topically
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25738970

Group type: EXPERIMENTAL
Intervention: Point of care H-FABP testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algorithm for triage combining signs, symptoms, and H-FABP testing
Number of subjects: 0
Study: 25739533

Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg BID
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg BID
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Dabigatran (both doses)
Number of subjects: 341
Study: 25739911

Group type: EXPERIMENTAL
Intervention: Targeted lung denervation at 20 W
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Targeted lung denervation at 15 W
Number of subjects: 22
Study: 25739926

Group type: EXPERIMENTAL
Intervention: Subjective Global Assessment (SGA) C
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Handgrip Strength (HGS)
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Reduced food intake during the first week of hospitalization
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: Food intake
Number of subjects: 733
Study: 25739929

Group type: EXPERIMENTAL
Intervention: (2)H-α-tocopherol from 120 g (2)H collard greens (1.2 ± 0.1 mg)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: (2)H-α-tocopherol
Number of subjects: 41
Study: 25739930

Group type: EXPERIMENTAL
Intervention: Long-chain ω-3 polyunsaturated fatty acids (LCω-3PUFAs) intake, upper quintile compared to lowest quintile
Number of subjects: 87360

Group type: EXPERIMENTAL
Intervention: Long-chain ω-3 polyunsaturated fatty acids (LCω-3PUFAs) intake
Number of subjects: 87360
Study: 25740400

Group type: EXPERIMENTAL
Intervention: Postoperative high-sensitive cardiac troponin T increase ≥100%
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Non-cardiac complications
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Hospital mortality
Number of subjects: 203
Study: 25740472

Group type: EXPERIMENTAL
Intervention: PELICAN I - Observational study of end-of-life care practices in hospital and home settings.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PELICAN II - Assessment of parents' experiences and needs during the end-of-life phase.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PELICAN III - Exploration of healthcare professionals' perspectives on end-of-life care.
Number of subjects: 0
Study: 25740780

Group type: EXPERIMENTAL
Intervention: Abbott RealTime HCV Genotype II
Number of subjects: 225

Group type: COMPARATOR
Intervention: Versant LiPA 2.0
Number of subjects: 225
Study: 25740829

Group type: EXPERIMENTAL
Intervention: Belimumab therapy for 24 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Belimumab therapy for 52 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Belimumab therapy
Number of subjects: 10
Study: 25740857

Group type: EXPERIMENTAL
Intervention: Oral mucosal disease (NIH Oral Mucosal Score, OMS)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Salivary dysfunction (saliva flow and xerostomia)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Limited mouth-opening
Number of subjects: 212
Study: 25741400

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate topical adhesive
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fast absorbing gut suture
Number of subjects: 14
Study: 25741894

Group type: EXPERIMENTAL
Intervention: Primary ED diagnosis
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Hospital discharge diagnosis
Number of subjects: 572

Group type: COMPARATOR
Intervention: Missed diagnoses in women
Number of subjects: 572

Group type: COMPARATOR
Intervention: Missed diagnoses in men
Number of subjects: 572
Study: 25742089

Group type: EXPERIMENTAL
Intervention: HIV-infected women with syphilis
Number of subjects: 1684

Group type: COMPARATOR
Intervention: HIV-exposed infants
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Newborns with symptomatic syphilis
Number of subjects: 1684
Study: 25742122

Group type: EXPERIMENTAL
Intervention: Standard Behavioral Weight Intervention (SBWI)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Stepped-Care Intervention (STEP)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Objective Physical Activity
Number of subjects: 346
Study: 25742126

Group type: EXPERIMENTAL
Intervention: Lung-protective ventilation
Number of subjects: 219

Group type: COMPARATOR
Intervention: Mechanical ventilation without lung-protective strategy
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Progression to ARDS
Number of subjects: 219
Study: 25742165

Group type: EXPERIMENTAL
Intervention: mAb7F9 (200 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: METH (0.1-0.56 mg/kg, s.c.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: METH (0.3 mg/kg, s.c.)
Number of subjects: 0
Study: 25742200

Group type: COMPARATOR
Intervention: miRNA107 expression in plasma
Number of subjects: 294

Group type: COMPARATOR
Intervention: BACE1 mRNA gene expression
Number of subjects: 294
Study: 25742699

Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (pt-Cy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Donor naive T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathogen-specific memory T cells
Number of subjects: 0
Study: 25743200

Group type: EXPERIMENTAL
Intervention: Bar graph illustration of fracture risk
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Pictogram illustration of fracture risk
Number of subjects: 142
Study: 25744334

Group type: EXPERIMENTAL
Intervention: Best-corrected visual acuity (BCVA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intraocular pressure (IOP)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Refraction
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Visual fields
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Residual RPE area on FAF
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Neuroretinal volume
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Age at examination
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Progressive loss of retinal area and volume
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Symmetry between eyes
Number of subjects: 29
Study: 25744975

Group type: EXPERIMENTAL
Intervention: Biogeographic ancestry (BGA)
Number of subjects: 656
Study: 25746631

Group type: EXPERIMENTAL
Intervention: Bronchoscopic transparenchymal nodule access (BTPNA) procedure
Number of subjects: 12
Study: 25747572

Group type: EXPERIMENTAL
Intervention: HbA1c <7% (53 mmol/mol)
Number of subjects: 220

Group type: COMPARATOR
Intervention: HbA1c >7% (53 mmol/mol)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Patients with ED
Number of subjects: 220
Study: 25748567

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 0
Study: 25748606

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: GIP
Number of subjects: 19

Group type: COMPARATOR
Intervention: NaCl (Control)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 19
Study: 25748634

Group type: EXPERIMENTAL
Intervention: Physical activity (≥ 60 min/d)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Screen time (≤ 2 h/d)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable intake (≥ 5 servings/d)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage avoidance
Number of subjects: 421
Study: 25748864

Group type: EXPERIMENTAL
Intervention: anti-TNF therapy
Number of subjects: 759
Study: 25749553

Group type: EXPERIMENTAL
Intervention: Gentle chest pressure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unprotected airway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Protected airway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Type of surgery (tonsillectomy/adenoidectomy vs other)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Age difference between groups
Number of subjects: 0
Study: 25749662

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m² rapid intravenous infusion on days 1, 4, 8, and 11, followed by pegylated liposomal doxorubicin 30 mg/m² intravenous infusion on day 4, up to 6 cycles.
Number of subjects: 3
Study: 25749986

Group type: EXPERIMENTAL
Intervention: Cixutumumab 10 mg/kg every 2 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cixutumumab 6-15 mg/kg weekly
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cixutumumab 6 mg/kg weekly
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cixutumumab 3-15 mg/kg weekly
Number of subjects: 40
Study: 25750589

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 8246

Group type: COMPARATOR
Intervention: Enoxaparin/VKA
Number of subjects: 8246
Study: 25751105

Group type: EXPERIMENTAL
Intervention: Activin A (ActA) concentrations in cachectic patients (CC)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Myostatin (Mstn) concentrations in cachectic patients (CC)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cachexia syndrome
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Anorexia (SNAQ score < 14)
Number of subjects: 152
Study: 25751770

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 6539

Group type: EXPERIMENTAL
Intervention: Vigorous physical activity (VPA)
Number of subjects: 6539

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 6539

Group type: EXPERIMENTAL
Intervention: MVPA (tertiles)
Number of subjects: 6539

Group type: EXPERIMENTAL
Intervention: Sedentary time (tertiles)
Number of subjects: 6539

Group type: EXPERIMENTAL
Intervention: MVPA
Number of subjects: 6539

Group type: EXPERIMENTAL
Intervention: VPA
Number of subjects: 6539

Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Number of subjects: 6539
Study: 25752885

Group type: EXPERIMENTAL
Intervention: Integrative care (AIC) program with ≥ 4 CM treatments
Number of subjects: 102

Group type: COMPARATOR
Intervention: Non-AIC group (n = 28)
Number of subjects: 102
Study: 25752898

Group type: EXPERIMENTAL
Intervention: Early resting computed tomography perfusion (rCTP)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: CCTA/rCTP
Number of subjects: 183

Group type: COMPARATOR
Intervention: CCTA/SPECT-MPI
Number of subjects: 183
Study: 25752990

Group type: EXPERIMENTAL
Intervention: VV' alternans triplets (>69%)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: VV' alternans triplets in the highest quartile
Number of subjects: 234

Group type: COMPARATOR
Intervention: ICD shock for fast ventricular tachycardia (FVT, cycle length ≤240 ms)/ventricular fibrillation (VF)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Nonarrhythmic death
Number of subjects: 234
Study: 25753361

Group type: EXPERIMENTAL
Intervention: Regorafenib at 160 mg/day, 3 weeks out of 4
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Metabolic responders
Number of subjects: 105

Group type: COMPARATOR
Intervention: Metabolic non-responders
Number of subjects: 105
Study: 25753432

Group type: COMPARATOR
Intervention: Sibling donors
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Unrelated donors
Number of subjects: 411
Study: 25753604

Group type: EXPERIMENTAL
Intervention: Parenteral Amino Acid Therapy (250 cc of AAs 3 times per week postdialysis for 8 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 23
Study: 25753656

Group type: EXPERIMENTAL
Intervention: Abnormal abdominal computed tomography (aCT)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Normal abdominal computed tomography (aCT)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Abnormal abdominal computed tomography (aCT) in reclassified Rai 0 patients
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: β-2 microglobulin
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: CD38 expression
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Clinical monoclonal B-cell lymphocytosis (cMBL)
Number of subjects: 181
Study: 25753965

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Baseline aggregation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Postoperative platelet turnover and acute-phase reaction
Number of subjects: 40
Study: 25755288

Group type: EXPERIMENTAL
Intervention: Dyx ≤ 1.96
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Normal Dyx
Number of subjects: 248
Study: 25755291

Group type: EXPERIMENTAL
Intervention: BR-ibrutinib (bendamustine and rituximab with ibrutinib 420 mg daily)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: FCR-ibrutinib (fludarabine, cyclophosphamide, and rituximab with ibrutinib 420 mg daily)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: BR-ibrutinib
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: FCR-ibrutinib
Number of subjects: 33
Study: 25755685

Group type: EXPERIMENTAL
Intervention: 13.3 mg/24 h rivastigmine patch
Number of subjects: 536

Group type: COMPARATOR
Intervention: 9.5 mg/24 h rivastigmine patch
Number of subjects: 536
Study: 25756303

Group type: EXPERIMENTAL
Intervention: CAPROS supplementation (500 mg b.i.d for 12 weeks)
Number of subjects: 0
Study: 25756398

Group type: EXPERIMENTAL
Intervention: Sunitinib treatment
Number of subjects: 105
Study: 25757508

Group type: EXPERIMENTAL
Intervention: Platelet mitochondrial respiratory chain enzymes activity in patients with sepsis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Platelet aggregation and secretion in response to exogenous agonists in patients with sepsis
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Correlation of mitochondrial enzyme activity with platelet aggregation in patients with sepsis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Platelet mitochondrial respiratory chain enzymes activity in patients with cardiogenic shock
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy volunteers as controls for spectrophotometry and lumiaggregometry
Number of subjects: 32
Study: 25757607

Group type: EXPERIMENTAL
Intervention: Prolonged-release oxycodone/naloxone (PR OXN) for 12 weeks (median daily dose, 20 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Prolonged-release oxycodone (PR OXY)
Number of subjects: 68
Study: 25757808

Group type: EXPERIMENTAL
Intervention: Educational intervention based on therapeutic home advice and a reminder app
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reminder app installed on mobile phones
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Various tests and scales (Barthel Index, Functional Independence Measure, etc.)
Number of subjects: 80
Study: 25758058

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 10 mg to 400 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50, 200, and 400 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25758261

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at 2 years
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) interruption
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) treatment
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 1900
Study: 25758611

Group type: EXPERIMENTAL
Intervention: 1×dose (1.1×10(11) vg/hemisphere, unilateral or bilateral injection)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5×dose (5.5×10(11) vg/hemisphere, bilateral injection)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1×dose
Number of subjects: 0
Study: 25758746

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg twice daily
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Dasatinib with intrapatient dose escalation by 50 mg daily every cycle as tolerated
Number of subjects: 77
Study: 25760881

Group type: EXPERIMENTAL
Intervention: Microvascular angina diagnosis and treatment
Number of subjects: 0
Study: 25761057

Group type: EXPERIMENTAL
Intervention: Fetuses of obese pregnant women (FOW)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fetuses of normal-weight pregnant women
Number of subjects: 80
Study: 25761109

Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg) administered in up to four cycles at 3-week intervals
Number of subjects: 53
Study: 25761189

Group type: EXPERIMENTAL
Intervention: Higher TG/HDL-C levels (quintile 5)
Number of subjects: 602
Study: 25761431

Group type: EXPERIMENTAL
Intervention: Survey-based identification of FD cases
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Phone screening for FD symptoms
Number of subjects: 937

Group type: COMPARATOR
Intervention: Survey cases
Number of subjects: 937

Group type: COMPARATOR
Intervention: Survey controls
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Enrolled participants
Number of subjects: 937

Group type: EXPERIMENTAL
Intervention: Screen fails
Number of subjects: 937
Study: 25761894

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 32
Study: 25762180

Group type: EXPERIMENTAL
Intervention: Pacritinib (SB1518)
Number of subjects: 35
Study: 25762240

Group type: EXPERIMENTAL
Intervention: Open Mesh (OM) hernioplasties
Number of subjects: 335

Group type: COMPARATOR
Intervention: Open Non-mesh (OS) repairs
Number of subjects: 335

Group type: COMPARATOR
Intervention: Laparoscopic (LAP) repairs
Number of subjects: 335
Study: 25762343

Group type: EXPERIMENTAL
Intervention: RG7356 (humanized anti-CD44 antibody)
Number of subjects: 0
Study: 25762355

Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy using the body composition monitor (BCM)
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Clinical judgement
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Clinical judgement and bioimpedance
Number of subjects: 1092
Study: 25762533

Group type: EXPERIMENTAL
Intervention: Atropine (5 µg/kg) administered intravenously
Number of subjects: 60

Group type: COMPARATOR
Intervention: Baseline heart rate
Number of subjects: 60
Study: 25762808

Group type: EXPERIMENTAL
Intervention: Coffee intake (self-reported)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Caffeine-related metabolites (theophylline, caffeine, paraxanthine)
Number of subjects: 498
Study: 25763111

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 25
Study: 25763783

Group type: EXPERIMENTAL
Intervention: TFV disoproxil fumarate/FTC therapy
Number of subjects: 19
Study: 25763789

Group type: EXPERIMENTAL
Intervention: Targeted therapy for FGFR2 fusions
Number of subjects: 0
Study: 25763831

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 53
Study: 25763866

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (150 mg/kg body weight)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Number of subjects: 156
Study: 25764091

Group type: EXPERIMENTAL
Intervention: PanCan risk prediction models
Number of subjects: 718
Study: 25764096

Group type: EXPERIMENTAL
Intervention: 1 mL of blood in a single aerobic bottle
Number of subjects: 519

Group type: COMPARATOR
Intervention: 0.5 mL in aerobic and anaerobic bottles (control)
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: 1 mL in a single aerobic bottle
Number of subjects: 519
Study: 25765333

Group type: EXPERIMENTAL
Intervention: Bumetanide 0.05 mg/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bumetanide 0.1 mg/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bumetanide 0.2 mg/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bumetanide 0.3 mg/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bumetanide (all doses)
Number of subjects: 14